Vera Therapeutics Announces 2024 Annual Meeting of Stockholders on May 15, 2024
Ticker: VERA · Form: DEF 14A · Filed: Apr 3, 2024 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | DEF 14A |
| Filed Date | Apr 3, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Vera Therapeutics, Annual Meeting, Proxy Statement, Director Election, KPMG LLP
TL;DR
<b>Vera Therapeutics will host its 2024 Annual Meeting of Stockholders on May 15, 2024, via webcast, to elect directors and ratify auditors.</b>
AI Summary
Vera Therapeutics, Inc. (VERA) filed a Proxy Statement (DEF 14A) with the SEC on April 3, 2024. Vera Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on May 15, 2024, at 8:00 a.m. Pacific Time. The meeting will be conducted via live webcast at www.virtualshareholdermeeting.com/VERA2024. Stockholders will vote on the election of two Class III directors to serve until the 2027 annual meeting. The appointment of KPMG LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024, will be ratified. The record date for determining stockholders entitled to vote is March 18, 2024.
Why It Matters
For investors and stakeholders tracking Vera Therapeutics, Inc., this filing contains several important signals. This filing is a proxy statement (DEF 14A) detailing the agenda and logistics for the annual meeting, which is crucial for shareholder governance and decision-making. The meeting will address the election of directors and the ratification of the independent auditor, key components of corporate oversight and financial integrity.
Risk Assessment
Risk Level: low — Vera Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or strategic shifts, indicating low immediate risk.
Analyst Insight
Stockholders should review the proxy materials to make informed decisions regarding director elections and auditor ratification at the upcoming annual meeting.
Key Numbers
- May 15, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders.)
- 8:00 a.m. (Pacific Time) — Annual Meeting Time (Time the Annual Meeting will commence.)
- March 18, 2024 — Record Date (Date to determine eligible stockholders.)
- 2027 — Director Term End (Year for which Class III directors are elected.)
Key Players & Entities
- Vera Therapeutics, Inc. (company) — Registrant and filer of the proxy statement.
- May 15, 2024 (date) — Date of the Annual Meeting of Stockholders.
- KPMG LLP (company) — Proposed independent registered public accounting firm.
- March 18, 2024 (date) — Record date for determining stockholders eligible to vote.
- 2027 (date) — Year until which elected directors will hold office.
FAQ
When did Vera Therapeutics, Inc. file this DEF 14A?
Vera Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 3, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Vera Therapeutics, Inc. (VERA).
Where can I read the original DEF 14A filing from Vera Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Vera Therapeutics, Inc..
What are the key takeaways from Vera Therapeutics, Inc.'s DEF 14A?
Vera Therapeutics, Inc. filed this DEF 14A on April 3, 2024. Key takeaways: Vera Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on May 15, 2024, at 8:00 a.m. Pacific Time.. The meeting will be conducted via live webcast at www.virtualshareholdermeeting.com/VERA2024.. Stockholders will vote on the election of two Class III directors to serve until the 2027 annual meeting..
Is Vera Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, Vera Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or strategic shifts, indicating low immediate risk.
What should investors do after reading Vera Therapeutics, Inc.'s DEF 14A?
Stockholders should review the proxy materials to make informed decisions regarding director elections and auditor ratification at the upcoming annual meeting. The overall sentiment from this filing is neutral.
How does Vera Therapeutics, Inc. compare to its industry peers?
Vera Therapeutics operates in the pharmaceutical preparations industry, focusing on the development of treatments for specific diseases.
Are there regulatory concerns for Vera Therapeutics, Inc.?
This filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.
Industry Context
Vera Therapeutics operates in the pharmaceutical preparations industry, focusing on the development of treatments for specific diseases.
Regulatory Implications
This filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.
What Investors Should Do
- Review the proxy statement for details on director nominees and their qualifications.
- Understand the proposal to ratify KPMG LLP as the independent auditor for fiscal year 2024.
- Prepare to vote on the matters presented at the Annual Meeting of Stockholders on May 15, 2024.
Key Dates
- 2024-05-15: Annual Meeting of Stockholders — Election of directors and ratification of auditors.
- 2024-03-18: Record Date — Determines stockholders eligible to vote at the Annual Meeting.
Year-Over-Year Comparison
This is a DEF 14A filing for the 2024 Annual Meeting, following previous filings related to corporate governance and financial reporting.
Filing Stats: 4,638 words · 19 min read · ~15 pages · Grade level 11.7 · Accepted 2024-04-03 17:00:53
Filing Documents
- ny20021839x1_def14a.htm (DEF 14A) — 647KB
- logo_vera.jpg (GRAPHIC) — 23KB
- sig_fordyce.jpg (GRAPHIC) — 20KB
- ny20021839x1_pc01.jpg (GRAPHIC) — 539KB
- ny20021839x1_pc02.jpg (GRAPHIC) — 520KB
- 0001140361-24-017650.txt ( ) — 2165KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT ​ ​ 19 Delinquent Section 16(a) Reports ​ ​ 21
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION ​ ​ 22 Summary Compensation Table ​ ​ 22 Annual Base Salary ​ ​ 23 Cash Incentive Compensation ​ ​ 23 Pension Benefits ​ ​ 24 Nonqualified Deferred Compensation ​ ​ 24 Agreements with Our Named Executive Officers ​ ​ 24 Outstanding Equity Awards at Fiscal Year End ​ ​ 25 Potential Payments Upon Termination or Change of Control ​ ​ 26 Other Compensation and Benefits ​ ​ 27 Employee Benefit Plans ​ ​ 27 401(k) Plan ​ ​ 27 Equity Compensation Plan Information ​ ​ 28 Limitations on Liability and Indemnification ​ ​ 28 Director Compensation ​ ​ 29 TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION ​ ​ 31 Investors’ Rights Agreement ​ ​ 31 Participation in 2022 Follow-on Public Offering ​ ​ 31 Participation in 2023 Follow-on Public Offering ​ ​ 31 Participation in 2024 Follow-on Public Offering ​ ​ 32 Employment Agreements and Stock Option Grants to Directors and Executive Officers ​ ​ 33 Indemnification ​ ​ 33 Policies and Procedures for Transactions with Related Persons ​ ​ 33 HOUSEHOLDING OF PROXY MATERIALS ​ ​ 34 OTHER MATTERS ​ ​ 35 i TABLE OF CONTENTS VERA THERAPEUTICS, INC. 8000 Marina Boulevard, Suite 120 Brisbane, California 94005 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 15, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the “SEC”), we have elected to provide access to our prox